News

W. Lloyd Clark, MD, presents results of the nonproliferative diabetic retinopathy-focused PANORAMA study during the 2021 ASRS annual meeting.

Investigators sought to develop a severity scale for tomographic edema in FECD based on Scheimpflug tomography maps, and to evaluate intra- and inter-observer variation for assessing severity.

According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.

Investigators find that estradiol drops can ease signs and symptoms of DED.

A cross sectional study investigated how chronic pain conditions outside of the eye impact corneal sensitivity.

According to investigators, the BNT162b2 (Pfizer–BioNTech) vaccine appears to be highly effective in preventing hospital admissions for up to about 6 months after vaccine recipients are fully vaccinated

The company will move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data.

iCare USA’s EIDON Ultra-Widefield Lens module has received FDA 510 (k) approval for distribution across the United States, the company announced Wednesday.

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Factors that lead to complications must be managed for best outcomes.

A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.

According to researchers at the University of Virginia School of Medicine, common HIV drugs or a safer alternative could stop vision loss.

Sustained-release option helps with patient adherence following surgery.

A literature review indicates that intravitreal administration of anti-VEGF drugs are effective for treating DME, but close attention should be paid to the potential for elevated IOP, cataract progression.

Researchers consider frequency and factors in etiology of complication

A word from Chief Medical Editor Peter J. McDonnell, MD.

Study: Older age and eyes with severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy had a higher risk of a vision loss event.

Nasotemporal sagittal height asymmetry a good biomarker of shortsightednes.

Anterior uveitis therapy offers anti-inflammatory effect after dosing is stopped.

Graybug Vision reported Tuesday a full-data analysis from the phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

The screening device works by assessing the eyes’ ability to fixate together. Held 14 inches from the eyes, the child fixates on a smiley face while the device simultaneously scans both retinas.

Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab.

Investigators learn that a wearable aid can offer improved mobility.

Adolf Fercher's 2D image of fundus paved way for today’s imaging technique.

According to a survey commissioned by Allergan, an AbbVie company, 65% of respondents said they were not prepared to have their vision worsen as they aged.

In the weeks leading up to the October awareness day, the International Agency for the Prevention of Blindness has revealed a campaign to encourage one million people to pledge to have a vision test.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.